Hot-Melt Extruded Amorphous Solid Dispersion for Solubility, Stability, and Bioavailability Enhancement of Telmisartan

Telmisartan (TEL, an antihypertensive drug) belongs to Class II of the Biopharmaceutical Classification System (BCS) because of its poor aqueous solubility. In this study, we enhanced the solubility, bioavailability, and stability of TEL through the fabrication of TEL-loaded pH-modulated solid dispe...

Full description

Saved in:
Bibliographic Details
Main Authors: Bhupendra Raj Giri (Author), Jaewook Kwon (Author), Anh Q. Vo (Author), Ajinkya M. Bhagurkar (Author), Suresh Bandari (Author), Dong Wuk Kim (Author)
Format: Book
Published: MDPI AG, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cb7abd78f9974b5795e451f6b9c6ac4c
042 |a dc 
100 1 0 |a Bhupendra Raj Giri  |e author 
700 1 0 |a Jaewook Kwon  |e author 
700 1 0 |a Anh Q. Vo  |e author 
700 1 0 |a Ajinkya M. Bhagurkar  |e author 
700 1 0 |a Suresh Bandari  |e author 
700 1 0 |a Dong Wuk Kim  |e author 
245 0 0 |a Hot-Melt Extruded Amorphous Solid Dispersion for Solubility, Stability, and Bioavailability Enhancement of Telmisartan 
260 |b MDPI AG,   |c 2021-01-01T00:00:00Z. 
500 |a 10.3390/ph14010073 
500 |a 1424-8247 
520 |a Telmisartan (TEL, an antihypertensive drug) belongs to Class II of the Biopharmaceutical Classification System (BCS) because of its poor aqueous solubility. In this study, we enhanced the solubility, bioavailability, and stability of TEL through the fabrication of TEL-loaded pH-modulated solid dispersion (TEL pH<sub>M</sub>-SD) using hot-melt extrusion (HME) technology. We prepared different TEL pH<sub>M</sub>-SD formulations by varying the ratio of the drug (TEL, 10-60% <i>w</i>/<i>w</i>), the hydrophilic polymer (Soluplus<sup>®</sup>, 30-90% <i>w/w</i>), and pH-modifier (sodium carbonate, 0-10% <i>w</i>/<i>w</i>). More so, the tablets prepared from an optimized formulation (F8) showed a strikingly improved in vitro dissolution profile (~30-fold) compared to the free drug tablets. The conversion of crystalline TEL to its amorphous state is observed through solid-state characterizations. During the stability study, F8 tablets had a better stability profile compared to the commercial product with F8, showing higher drug content, low moisture content, and negligible physical changes. Moreover, compared to the TEL powder, in vivo pharmacokinetic studies in rats showed superior pharmacokinetic parameters, with maximum serum concentration (C<sub>max</sub>) and area under the drug concentration-time curve (AUC<sub>0</sub>-<sub>∞</sub>) of the TEL pH<sub>M</sub>-SD formulation increasing by 6.61- and 5.37-fold, respectively. Collectively, the results from the current study showed that the inclusion of a hydrophilic polymer, pH modulator, and the amorphization of crystalline drugs in solid dispersion prepared by HME can be an effective strategy to improve the solubility and bioavailability of hydrophobic drugs without compromising the drug's physical stability. 
546 |a EN 
690 |a telmisartan 
690 |a pH-modifier 
690 |a solid dispersion 
690 |a hot-melt extrusion (HME) 
690 |a solubility 
690 |a bioavailability 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 14, Iss 1, p 73 (2021) 
787 0 |n https://www.mdpi.com/1424-8247/14/1/73 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/cb7abd78f9974b5795e451f6b9c6ac4c  |z Connect to this object online.